ALZA, a company specializing in drug delivery systems such as transdermal patches, according to the manufacture of its products. So far, the company has carried out research and development on its patented, but then licensed client-partner companies such as Ciba-Geigy, which produce patches and slow-release tablets. These client-partner is always selected drugs should be included in the system on the basis of their experience in the pharmaceutical markets. In addition, these partners have made the entire production. Students are asked to consider the implications of ALZA to take responsibility not only for the choice of products and markets, on its own, but also to manage large volumes of production capacity. The case focuses on a potentially risky business requires a whole set of new features. "Hide
by Dorothy Leonard-Barton, Allegra Young Source: Harvard Business School 15 pages. Publication Date: September 2, 1993. Prod. #: 694019-PDF-ENG
Related Case Solutions & Analyses:
Andy Chew at Siemens Nixdorf: Change from the Middle
Apple Computer–1996
SouthPark IV
Nike in China (Abridged)
Creative Confidence: The Path From Blank Page to Insight
Rough Justice: Stuart Eizenstat and Holocaust-Era Asset Restitution (B)
JetBlue Airways (IPO process)
Ethical Issues In Business
DRINKWISE CASE – PART 2, CALLING TIME
AFRICAN TEA BAGS FOR EUROPE: THE CASE OF SUPERWE
